What is HC Wainwright’s Forecast for KALV FY2028 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – HC Wainwright decreased their FY2028 earnings estimates for shares of KalVista Pharmaceuticals in a report issued on Friday, March 27th. HC Wainwright analyst A. Fein now expects that the specialty pharmaceutical company will post earnings per share of $2.06 for the year, down from their previous estimate of $2.25. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

Several other equities research analysts have also recently commented on KALV. TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Stifel Nicolaus boosted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday. Wall Street Zen upgraded KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Citizens Jmp lowered their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday. Finally, Needham & Company LLC boosted their price target on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $19.33 on Monday. The company has a 50 day moving average of $16.04 and a 200-day moving average of $14.45. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The firm has a market cap of $990.08 million, a P/E ratio of -4.89 and a beta of -0.35. KalVista Pharmaceuticals has a twelve month low of $9.23 and a twelve month high of $19.95.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Tudor Investment Corp ET AL acquired a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $24,360,000. Vestal Point Capital LP lifted its position in shares of KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after purchasing an additional 905,053 shares during the period. Finally, Elmind Capital LP purchased a new position in KalVista Pharmaceuticals during the 4th quarter worth approximately $12,941,000.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CFO Brian Piekos sold 1,767 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the transaction, the chief financial officer owned 13,762 shares in the company, valued at $214,274.34. This trade represents a 11.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $16.08, for a total value of $107,623.44. Following the completion of the transaction, the chief executive officer owned 451,815 shares of the company’s stock, valued at $7,265,185.20. This trade represents a 1.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 248,009 shares of company stock worth $4,213,467. 4.30% of the stock is owned by insiders.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.